Atara Biotherapeutics, Inc. (NASDAQ: ATRA) today announced President and Chief Executive Officer Pascal Touchon will share details of the company's mission, scientific platform and development pipeline during a presentation at the 38th Annual J.P. Morgan Healthcare Conference on Thursday, January 16 at 8:30 a.m. PST at the Westin St. Francis Hotel in San Francisco.
"As we enter into this new year, we are proud of our progress building a leading off-the-shelf, allogeneic T-cell immunotherapy company with a robust pipeline," said Pascal Touchon, President and Chief Executive Officer of Atara Biotherapeutics. "Backed by our innovative EBV T-cell platform, next-generation CAR T technologies, state-of-the-art manufacturing capabilities and dedication to developing transformative T-cell immunotherapies for patients, we are confident in our ability to execute on our 2020 plans."
Anticipated key milestones across Atara's four strategic priorities in 2020 include:
Submitted clinical trial applications (CTAs) to several European countries in November 2019 to enable opening EU clinical sites in 2020
Begin enrollment in a Phase 2 multi-cohort study including patients with other EBV+ cancers in the second half of 2020
Initiate FDA Biologics License Application (BLA) submission for patients with EBV+ PTLD in the second half of 2020
Initiate enrollment of randomized, double-blind, placebo-controlled Phase 1b study in patients with progressive MS in the second or third quarter of 2020
Present six- and twelve-month ATA188 Phase 1a clinical results for cohorts 3 and 4 in the first and second halves of 2020, respectively
Submit next-generation mesothelin-targeted autologous CAR T IND for patients with advanced mesothelioma in the second or third quarter of 2020
EBV CAR T Platform
Academic presentation of an off-the-shelf, allogeneic CD19 CAR T clinical proof-of-principle using a partially HLA matched Epstein-Barr virus T cell academic construct for patients with relapsed/refractory B-cell malignancies at the 2020 Transplantation and Cellular Therapy (TCT) Meetings to be held February 19-23 in Orlando, Fla.